Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announced that recruitment of the Group’s Phase III clinical trial with PQ Birch (PQBirch301) has..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces it has entered into a co-development collaboration agreement with Ergomed plc (LON:ERGO) for the..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announced today that Manuel Llobet, Chief Executive Officer, will be presenting at the Jefferies 2017 Healthcare..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announced that dosing has commenced in its G205 Phase II study designed to evaluate the..
Allergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in the EU only..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announced its preliminary results for the year ended 30 June 2017. Financial highlights · 72%..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announced that the fully-funded Phase II clinical trial investigating the dosing of PQ Grass has..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announced new senior appointments and expansion of the R&D and clinical team in line with..
Allergy Therapeutics Plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, will issue its preliminary results for the year ended 30 June 2017 on Thursday 28 September..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today provided a trading update for the year ended 30 June 2017 ahead of its Preliminary..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, is hosting a site visit at its corporate headquarters for sell-side analysts today and institutional investors..
Allergy Therapeutics plc (LON:AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announced tody the appointment of Dr Tunde Otulana to its Board of Directors as a Non-Executive..
Allergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in EU only on..
Allergy Therapeutics Plc (LON:AGY) the UK-based, specialty pharmaceutical company focused on the development, manufacture and sale of vaccines and other products for the treatment and prevention of allergies, today reported..
Allergy Therapeutics Plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announced today that the recruitment of the first patient in its Phase III study designed to..
Zeus Capital Director of Healthcare Research Dr Gary Waanders caught up with DirectorsTalk for an exclusive interview to discuss Allergy Therapeutics plc (LON:AGY) Q1: Now, Allergy Therapeutics announced today..
Allergy Therapeutics Plc (LON:AGY) is the topic of conversation with Dr Gary Waanders Director of Healthcare Research at Zeus Capital. Since Allergy Therapeutics announced today that it has obtained approval..
Allergy Therapeutics plc (LON:AGY) is a UK-based, specialty pharmaceutical company focused on the development, manufacture and sale of vaccines and other products for the treatment and prevention of allergies. This..
Allergy Therapeutics plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Trials to obtain full regulatory approval as a biological for its ultra short-course immunotherapy,..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces the appointment of Mr Jeff Barton to the Company’s Board as a Non-Executive Director, nominated..
